# Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)

> **NCT02657447** · PHASE1 · WITHDRAWN · sponsor: **Nordic Nanovector**

## Conditions studied

- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Betalutin with lilotomab dose 1
- **DRUG:** Betalutin with lilotomab dose 2

## Key facts

- **NCT ID:** NCT02657447
- **Lead sponsor:** Nordic Nanovector
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-12-19
- **Primary completion:** 2019-09
- **Final completion:** 2020-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study is no longer relevant
- **Last updated:** 2019-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02657447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02657447, "Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02657447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*